Eyes On Chugai's Hemlibra Supply Price As Sales Grow
Set against what were seen as solid third quarter results, analysts are keeping an eye on planned changes to Chugai's supply price of Hemlibra to global licensee Roche.
You may also be interested in...
While Chugai’s satralizumab may not be odds on to win the race for approval, it may beat Alexion’s Soliris on ease of use with a regimen of subcutaneous application once a month versus Soliris’ fortnightly IV.
Genentech/Roche's Hemlibra, now FDA-approved for hemophilia A patients with inhibitors, offers a once-weekly injection, impressive efficacy with a safety concern that appears to be manageable, and a price that's at least half the cost of the established prophylaxis regimen.
Japanese firm and key discoverer of immuno-oncology protein reach settlement of patent-related dispute that includes formation of new academic research fund.